Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
CA 2392764 A1 · Owner: Sette, Alessandro · Inventors: Fikes, John; Southwood, Scott; Sette, Alessandro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare carcino-embryonic antigen (CEA) epitopes, and to develop epitope-based vaccines directed towards CEA-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 11, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 11, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 11, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.